A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was published in the 30 September 2011 issue of the Journal “Cell” [I.F: 33.116] by Prof Daley GQ, Zhu H, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based Regenerative therapy for DM: MiRNA-25 promotes an insulin-sensitized state via up regulation of reprogramming protein Lin28
Significance: Prof. Daley GQ and his team members have shown that loss of Lin28 promotes insulin resistance and glucose intolerance. The study presented here suggests, for the first time, that MiRNA-25, by increasing the expression of its target gene, it may increase the expression of RNA-binding protein Lin-28, and thereby promote insulin sensitivity. Thus, pharmacological formulations encompassing ” MiRNA-25 activators” may be used to treat DM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How MiRNA-25 increases the expression of Lin28
To cite: Boominathan, MiRNA-based Regenerative therapy for DM: MiRNA-25 promotes an insulin sensitized state via up regulation of reprogramming protein Lin28, 2/April/2015, 17.30, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation